^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:MRG001 (Microtubule inhibitor, CD20-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Blood
    Title:

    A Dose Escalation Phase Ia Study of Anti-CD20 Antibody Drug Conjugate, MRG001 in Relapsed/Refractory Advanced Non-Hodgkin Lymphom

    Published date:
    11/23/2021
    Excerpt:
    MRG001 was evaluated as a monotherapy for the treatment of patients with confirmed CD20-positive R/R B-cell NHL….The dose escalation study of MRG001 has shown manageable safety profiles and encouraging preliminary antitumor activity in patients with NHL.
    DOI:
    https://doi.org/10.1182/blood-2021-144829